Over the last decade, stem cell therapy has moved from experimental curiosity to one of the most talked-about frontiers in modern medicine. Among the most promising types are mesenchymal stem/stromal cells (MSCs) derived from Wharton’s jelly, a gelatinous tissue inside the umbilical cord. These MSCs are prized because they are young, potent, and immune-privileged, meaning they can be used in recipients without triggering strong rejection responses.
Delivered intravenously (IV), Wharton’s Jelly MSCs may modulate inflammation, promote repair, reduce fibrosis, and rejuvenate tissue function throughout the body. Patients are asking whether these therapies are truly effective, what risks are involved, and whether they are legally and safely available in the United States.
This FAQ will explore the latest evidence on stem cell IV therapy using Wharton’s Jelly MSC’s, with a focus on degenerative diseases, lung fibrosis, long-haul COVID, organ regeneration, and anti-aging applications. It will also cover side effects, safety, and how you can access safe MSC Stem Cell IV therapy in the United States.
Frequently Asked Questions About MSC Stem Cell IV Therapy
1. What exactly are Wharton’s Jelly and Umbilical Cord–Derived MSCs?
Wharton’s Jelly is a gelatinous, nutrient-rich connective tissue inside the umbilical cord, surrounding the blood vessels. It is an abundant source of mesenchymal stem/stromal cells (MSCs).
Wharton’s Jelly MSCs are valued because:
- They are non-embryonic, making them ethically sourced and acceptable.
- They have robust proliferation and differentiation potential.
- They are immune-privileged, reducing risk of rejection.
- They release powerful growth factors, cytokines, and exosomes that help regenerate tissue.
Compared with bone marrow or adipose-derived MSCs, umbilical cord MSCs are younger and show greater regenerative potential.
2. What makes Wharton’s Jelly MSCs different from bone marrow or adipose MSCs?
- Bone marrow MSCs: Fewer in number, older (senescent), require invasive harvest.
- Adipose MSCs: Abundant but may show donor age-related decline.
- Wharton’s Jelly MSCs:
- Abundant, youthful, highly proliferative.
- Low immunogenicity.
- Ethically sourced from healthy, screened donors.
- Do not require invasive harvesting from the patient.
This makes Wharton’s Jelly MSC stem cells ideal for IV infusions.
3. How do MSC Stem Cell IV infusions work?
When delivered intravenously (IV):
- A portion of the cells lodge in the lungs first, where they exert strong anti-inflammatory and anti-fibrotic effects.
- MSCs then secrete paracrine factors (growth factors, cytokines, exosomes) that circulate systemically.
- These signals help reduce inflammation, promote angiogenesis, inhibit fibrosis, and stimulate native tissue repair.
- Unlike organ transplants, MSCs rarely “become” new tissue; instead, they direct the body’s healing response.
4. Can I get MSC stem cells in the United States?
Yes! Patients can legally access umbilical cord–derived MSC Stem Cell IV therapy at clinics like Balanced Medical Solutions, that source their stem cells from FDA regulated U.S.-based cord banks.
While only one MSC therapy (Ryoncil, remestemcel-L) is FDA-approved (for pediatric graft-versus-host disease), Balanced Medical Solutions in Hayward, California offers regenerative medicine therapies using ethically sourced MSCs in compliance with FDA safety standards. These standards include the methods for sourcing the cells from pre-screened, healthy donors, and they regulate how they are treated, stored, and transported.
5. What are the best-documented benefits of Wharton’s Jelly MSC IV therapy?
The strongest evidence points to benefits in immune modulation, fibrosis reduction, and tissue repair. Research is ongoing, but documented benefits include:
a) Degenerative Diseases
- Osteoarthritis & Degenerative Joint Disease: MSCs reduce inflammation, improve pain, and promote cartilage repair in early studies.
- Neurodegenerative Disorders (Parkinson’s, Alzheimer’s, MS): While research is early, MSCs have shown neuroprotective and anti-inflammatory effects in preclinical and small clinical trials.
b) Lung Fibrosis & Pulmonary Disease
- MSC Stem Cell IVs reduce fibrosis, scarring, and inflammatory cytokines in idiopathic pulmonary fibrosis (IPF) models.
- In COVID-19 ARDS trials, MSCs Stem Cells reduced mortality, hospital stay, and inflammation without major safety issues.
c) Long-Haul COVID
- Persistent inflammation, fatigue, and lung impairment define long COVID.
- MSCs, through immune recalibration and tissue repair signaling, are showing early promise in restoring lung function and reducing systemic inflammation.
d) Regeneration of Organ Damage
- Liver Disease: Meta-analyses show MSC IV therapy improves liver function tests and fibrosis scores in cirrhosis and hepatitis.
- Kidney Disease: Early clinical studies demonstrate improved GFR, creatinine, and proteinuria in CKD patients after MSC stem cell infusion.
- Stroke/Brain Injury: MSC stem cells appear safe and may improve neurological recovery post-stroke.
e) Anti-Aging and Rejuvenation
- MSCs counter inflammaging, reduce oxidative stress, and stimulate collagen/skin regeneration.
- Patients report improved skin tone, hair growth, energy levels, and cognitive sharpness in early reports.
- Secretome and exosome-based therapies are being studied for wrinkle reduction and skin rejuvenation.
6. Are Wharton’s Jelly MSCs safe?
Most controlled clinical trials show MSCs are well-tolerated, with no significant increase in serious adverse events compared to placebo. The DNA of the donor is stripped from the cells, which reduces the risk of rejection and allows for the brand new MSC stem cells to adopt the DNA of the recipient.
Most common side effects:
- Mild fever
- Chills or fatigue
- Temporary infusion-related reactions (headache, flushing, nausea)
Rare but possible risks:
- Infusion reactions (shortness of breath, hypotension, hypersensitivity)
- Thrombosis (from blood-MSC interactions, mitigated with proper preparation)
- Infection or contamination if non-GMP products are used
- Theoretical tumor enlargement risk if patient has an unknown tumor in their body (not seen in large trials to date)
Key takeaway: With properly screened donors and clinical-grade preparation, Wharton’s Jelly MSC Stem Cell IVs are considered safe in clinical settings.
7. What conditions are being most actively studied with Wharton’s Jelly MSC Stem Cell IVs?
- Pulmonary fibrosis and ARDS (COVID-19 and non-COVID causes)>
- Liver cirrhosis and fibrosis
- Chronic kidney disease
- Neurological conditions (stroke recovery, MS, Alzheimer’s)
- Autoimmune diseases (rheumatoid arthritis, lupus)
- Skin repair and anti-aging, including hair regrowth.
8. How are donor umbilical cords screened?
At reputable clinics like Balanced Medical Solutions:
- Donors are healthy, pre-screened mothers who deliver via scheduled cesarean section.
- Cords are processed under GMP (Good Manufacturing Practice) and FDA regulations.
- Donor mothers are screened for infectious diseases (HIV, hepatitis, syphilis, CMV, etc.).
- MSC stem cells are isolated, tested, and expanded in controlled labs before being used.
This ensures safety, sterility, and potency.
9. How long do results last?
This depends on:
- Condition treated
- Severity of disease
- Number of infusions
- Lifestyle factors (diet, exercise, hormone balance)
For example:
- In inflammatory/fibrotic diseases (like lung fibrosis), studies show functional improvements lasting months to years.
- In anti-aging contexts, effects may be more subtle and gradual, often requiring periodic maintenance.
10. Are results immediate?
Some patients report feeling increased energy, better sleep, and improved breathing within weeks, while others notice gradual changes over several months.
Because MSCs stem cells reprogram immune and repair processes, benefits often accumulate rather than being instantaneous.
11. How many MSC IV sessions are needed?
- Degenerative disease/fibrosis: Often a series of infusions spaced weeks to months apart.
- Anti-aging: Sometimes annual or semi-annual boosters are recommended.
- Clinical trials vary, but 1–3 sessions are typical in early studies.
Your provider will tailor dosing based on condition and lab results.
12. Are these treatments FDA-approved?
- Yes, but only in one case: The FDA has approved remestemcel-L (Ryoncil), an MSC therapy for pediatric graft-versus-host disease.
- For anti-aging, lung fibrosis, osteoarthritis, long COVID, and degenerative disease, MSC IVs remain investigational in the U.S. and are only offered at clinics like Balanced Medical Solutions for early adopters who wish to access this therapy “off-label.”
At Balanced Medical Solutions, patients receive careful screening, lab work, and medical oversight to qualify for the treatment.
13. How many stem cells are in a MSC Stem cell IV?
The standard dose of 1ml or cc’s of MSC stem cells contains between 20-50 million cells. The range is wide because this is a biologic, non-standardized material. Patients can receive up to 5 doses in one IV bag to help achieve even better or faster results than spacing their single dose IV’s out every few months.
14. Who should avoid MSC Stem Cell IVs?
Contraindications include:
- Active systemic infections
- Uncontrolled cancers
- Severe cardiopulmonary instability
- Pregnant or breastfeeding women (not enough safety data)
- Patients with prior severe biologic infusion reactions
15. How do MSCs compare to exosomes?
- MSCs: Living cells that secrete paracrine factors.
- Exosomes: Nanoparticles secreted by MSCs, containing proteins, RNAs, and growth signals.
Exosome therapy is being studied as a cell-free alternative with potentially fewer risks and easier standardization. Balanced Medical Solutions offers exosomes for early adopters who would like to access this new treatment.
At present, both MSCs and MSC-derived exosomes are considered investigational for anti-aging and regeneration.
16. How do I get qualified for a MSC Stem Cell Infusion at Balanced Medical Solutions?
Balanced Medical Solutions offers comprehensive evaluations for San Francisco Bay Area proactive individuals looking to access this modern therapy while it is still undergoing clinical trials.
Patients visit Balanced Medical Solutions for this treatment because they understand that the safety and regulatory climate in the United States is much stricter than in Panama, Mexico, India or other countries. With Balanced Medical Solutions, patients can be at ease knowing the MSC stem cells are sourced ethically from donated umbilical cords and treated, transported, and stored under FDA guidelines.
Patients can be evaluated for MSC Stem Cell therapy for only $99. This includes:
- Comprehensive medical evaluation
- Comprehensive blood tests
- A personalized plan
- Free lifetime follow-ups to monitor your progress
This ensures your therapy is safe, tailored, and evidence-guided.
Conclusion: Should You Consider Wharton’s Jelly MSC IV Therapy?
MSC IV therapy from Wharton’s Jelly and umbilical cords is among the most exciting frontiers in regenerative medicine. Clinical evidence supports benefits for lung fibrosis, liver disease, kidney disease, degenerative disorders, and skin rejuvenation, with promising applications in long-COVID and anti-aging.
While most uses remain investigational, the safety profile is strong when using screened, GMP-prepared cells. Patients considering this therapy should seek reputable providers with medical oversight, such as Balanced Medical Solutions.
Schedule a comprehensive evaluation for just $99 (includes labs and free lifetime follow-ups). This allows you to safely explore whether MSC IV therapy aligns with your health and wellness goals.
Book now with hyperlinked to: https://balancedmedicalsolutions.com/book-now/
Sources:
- Leng, Zikuan, et al. “Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia.” Aging and Disease, vol. 11, no. 2, 2020, pp. 216–228. doi:10.14336/AD.2020.0228.
- Atluri, Suresh, et al. “Mesenchymal stem cell therapy for COVID-19: present status and future directions.” Stem Cell Research & Therapy, vol. 11, no. 1, 2020, p. 219. doi:10.1186/s13287-020-01725-8.
- Wang, Yu, et al. “Umbilical Cord–Derived Mesenchymal Stem Cells for Regenerative Medicine: A Review.” Frontiers in Cell and Developmental Biology, vol. 9, 2021, Article 653002. doi:10.3389/fcell.2021.653002.
- Shi, Yufang, et al. “Immunoregulatory Mechanisms of Mesenchymal Stem and Stromal Cells in Inflammatory Diseases.” Nature Reviews Nephrology, vol. 14, 2018, pp. 493–507. doi:10.1038/s41581-018-0023-5.
- Wang, Lijun, et al. “Mesenchymal Stem Cell-Derived Extracellular Vesicles in Regenerative Medicine: Applications and Challenges.” Stem Cell Research & Therapy, vol. 12, 2021, p. 156. doi:10.1186/s13287-021-02246-9.
- U.S. Food and Drug Administration (FDA). “Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.” FDA.gov, 2023.
- Hashemian, Seyed-Mohammad, et al. “Mesenchymal Stem Cells in Organ Fibrosis: Insight into Mechanisms, Therapeutic Potential, and Clinical Translation.” Stem Cell Research & Therapy, vol. 12, no. 1, 2021, p. 353. doi:10.1186/s13287-021-02457-0.
Pittenger, Mark F., et al. “Mesenchymal Stem Cell Perspective: Cell Biology to Clinical Progress.” NPJ Regenerative Medicine, vol. 4, no. 22, 2019. doi:10.1038/s41536-019-0083-6.
